| |
N (%)
|
Total person-years of follow-up
|
|---|
|
Total number of cases included in analysis
|
28,260
|
239,125.95
|
|
Female
|
14,678 (51.9)
| |
|
Age at IBD diagnosis
|
|
Diagnosed ≤ 65 years
|
17,662 (62.5)
| |
|
Diagnosed ≥ 65 years
|
5554 (19.7)
| |
|
Unknowna
|
5044 (17.9)
| |
|
Rural residenceb
|
4344 (15.4)
| |
|
Mean neighbourhood income quintile
|
|
Q1
|
4678 (16.7)
| |
|
Q2
|
5420 (19.4)
| |
|
Q3
|
5642 (20.2)
| |
|
Q4
|
5662 (20.3)
| |
|
Q5
|
6547 (23.4)
| |
|
Drug group
|
|
Immunomodulator Monotherapy
|
4789 (16.9)
|
12,141.96
|
|
Biologic Monotherapy
|
1381 (4.9)
|
3010.39
|
|
Combination therapy
|
844 (3.0)
|
1764.27
|
|
Mesalamine
|
17,625 (62.4)
|
81,128.99
|
|
No therapy
|
28,260 (100.0)
|
95,492.74
|
|
Systemic steroids
|
14,647 (51.8)
|
12,220.14
|
|
Type of IBD
|
|
Crohn’s disease
|
10,870 (38.5)
|
n/a
|
|
Ulcerative colitis
|
15,992 (56.6)
|
n/a
|
|
IBD-type unclassified
|
1398 (4.9)
|
n/a
|
- IBD inflammatory bowel disease
- aFirst diagnostic code for IBD occurred ≥ 65 years of age but did not have an 8-year washout period prior to first IBD code
- bAt first diagnostic code for IBD
